| Bioactivity | Idelalisib-d5 is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor[1]. | ||||||||||||
| Target | P110δ inhibitor | ||||||||||||
| Name | Idelalisib-d5 | ||||||||||||
| CAS | 1830330-31-8 | ||||||||||||
| Formula | C22H13D5FN7O | ||||||||||||
| Molar Mass | 420.45 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Lannutti BJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood, 2011, 117(2), 591-594. |
Idelalisib-d5
CAS: 1830330-31-8 F: C22H13D5FN7O W: 420.45
Idelalisib-d5 is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibit
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.